{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:32:33Z","timestamp":1793230353629,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.critrevonc.2026.105659","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T06:21:26Z","timestamp":1792563686000},"page":"105659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lung cancer organoid models for studying resistance to anti-angiogenic therapy: Mechanisms and applications"],"prefix":"10.1016","volume":"228","author":[{"given":"Hangfeng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105659_bib1","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-10-2847","article-title":"Brivanib, a dual FGF\/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive\/evasive resistance to VEGF inhibition","volume":"17","author":"Allen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib2","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1038\/s41467-024-48864-3","article-title":"Roadblocks confronting widespread dissemination and deployment of Organs on Chips","volume":"15","author":"Alver","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates Edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105659_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105659_bib5","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105659_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/path.4845","article-title":"Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models","volume":"241","author":"Bridgeman","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib7","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0226","article-title":"Applicability of drug response metrics for cancer studies using biomaterials","volume":"374","author":"Brooks","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105659_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105659_bib9","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-16-3216","article-title":"The HGF\/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer","volume":"23","author":"Cascone","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","article-title":"Tumor organoid-T-cell coculture systems","volume":"15","author":"Cattaneo","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.critrevonc.2026.105659_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.actbio.2021.01.023","article-title":"Influences of the 3D microenvironment on cancer cell behaviour and treatment responsiveness: A recent update on lung, breast and prostate cancer models","volume":"132","author":"Costard","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.critrevonc.2026.105659_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105659_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105659_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","article-title":"Organoids in cancer research","volume":"18","author":"Drost","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105659_bib15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105659_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2018.06.001","article-title":"Antiangiogenic therapy: Markers of response, \"normalization\" and resistance","volume":"128","author":"El Alaoui-Lasmaili","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib17","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202500301","article-title":"Organoid Vascularization: Strategies and Applications","volume":"14","author":"Gao","year":"2025","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.critrevonc.2026.105659_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105659_bib20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the Vasculature for Treatment of Cancer and Other Diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.critrevonc.2026.105659_bib21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.critrevonc.2026.105659_bib22","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303740120","article-title":"KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas","volume":"120","author":"Hosaka","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105659_bib23","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1038\/s41467-021-22676-1","article-title":"Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week","volume":"12","author":"Hu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib24","article-title":"Recent advances in vascularized tumor-on-a-chip","volume":"13","author":"Huang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib25","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105659_bib26","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3390\/cancers17142291","article-title":"Establishment of Human Lung Cancer Organoids Using Small Biopsy and Surgical Tissues","volume":"17","author":"Hwang","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105659_bib27","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib28","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: A web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.critrevonc.2026.105659_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105659_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.695038","article-title":"Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study","volume":"11","author":"Jantus-Lewintre","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib31","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.3390\/cancers16233996","article-title":"Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure","volume":"16","author":"Kang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105659_bib32","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib33","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","article-title":"Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib34","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3390\/genes15121624","article-title":"The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids","volume":"15","author":"Kobayashi","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105659_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12931-024-02855-6","article-title":"Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery","volume":"25","author":"Koziol-White","year":"2024","journal-title":"Respir. Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10456-019-09698-6","article-title":"Vessel co-option and resistance to anti-angiogenic therapy","volume":"23","author":"Kuczynski","year":"2020","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2026.105659_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10456-019-09690-0","article-title":"Pathological features of vessel co-option versus sprouting angiogenesis","volume":"23","author":"Latacz","year":"2020","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2026.105659_bib38","article-title":"Modeling the metastatic tumor microenvironment: A co-culture platform of lung cancer and blood vessel organoids for drug evaluation","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105659_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41698-024-00609-7","article-title":"Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion","volume":"8","author":"Lee","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43586-022-00118-6","article-title":"A guide to the organ-on-a-chip","volume":"2","author":"Leung","year":"2022","journal-title":"Nat. Rev. Methods Prim."},{"key":"10.1016\/j.critrevonc.2026.105659_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12964-023-01332-9","article-title":"Applications of lung cancer organoids in precision medicine: From bench to bedside","volume":"21","author":"Li","year":"2023","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105659_bib42","article-title":"Bridging the gap: How patient-derived lung cancer organoids are transforming personalized medicine","volume":"13","author":"Liu","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib43","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1039\/D3LC01044A","article-title":"Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells","volume":"24","author":"Luan","year":"2024","journal-title":"Lab. Chip"},{"key":"10.1016\/j.critrevonc.2026.105659_bib44","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.190703","article-title":"Living human lung slices for ex vivo modelling of lung cancer","volume":"10","author":"Mansouri","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.critrevonc.2026.105659_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1616","article-title":"Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models","volume":"13","author":"Martinez-Usatorre","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib48","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41551-024-01236-0","article-title":"Standardizing designed and emergent quantitative features in microphysiological systems","volume":"8","author":"Nahon","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105659_bib49","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jtho.2024.11.032","article-title":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","volume":"20","author":"Nakagawa","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119547","article-title":"Vascularized cancer on a chip: The effect of perfusion on growth and drug delivery of tumor spheroid","volume":"229","author":"Nashimoto","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.critrevonc.2026.105659_bib52","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid Modeling of the Tumor Immune Microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105659_bib53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10456-018-9613-x","article-title":"Consensus guidelines for the use and interpretation of angiogenesis assays","volume":"21","author":"Nowak-Sliwinska","year":"2018","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2026.105659_bib54","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.3390\/cancers13163930","article-title":"Three-Dimensional Vascularized Lung Cancer-on-a-Chip with Lung Extracellular Matrix Hydrogels for In Vitro Screening","volume":"13","author":"Park","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105659_bib55","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib56","first-page":"1417","article-title":"Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis","volume":"151","author":"Pezzella","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib57","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s41467-024-45710-4","article-title":"A microfluidic platform integrating functional vascularized organoids-on-chip","volume":"15","author":"Quintard","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aaf4405","article-title":"Hypoxic control of metastasis","volume":"352","author":"Rankin","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2026.105659_bib59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cllc.2017.01.004","article-title":"Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials","volume":"18","author":"Raphael","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105659_bib60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib62","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1323350","article-title":"Vascular co-option in resistance to anti-angiogenic therapy","volume":"13","author":"Ribatti","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib64","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105659_bib66","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1481726","article-title":"Vasculogenic mimicry in non-small cell lung cancer: A systematic review","volume":"15","author":"Shapkina","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib68","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-19-1376","article-title":"Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib69","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1039\/C8LC00596F","article-title":"Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids","volume":"18","author":"Shirure","year":"2018","journal-title":"Lab. Chip"},{"key":"10.1016\/j.critrevonc.2026.105659_bib70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-bioeng-090120-094330","article-title":"Engineering Vascularized Organoid-on-a-Chip Models","volume":"23","author":"Shirure","year":"2021","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.critrevonc.2026.105659_bib71","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1073\/pnas.0902280106","article-title":"G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models","volume":"106","author":"Shojaei","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2026.105659_bib72","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105659_bib73","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib74","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib75","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.3390\/ijms23168863","article-title":"Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)","volume":"23","author":"Tan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105659_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114323","article-title":"Organ-specific endothelial cell heterogenicity and its impact on regenerative medicine and biomedical engineering applications","volume":"186","author":"Urbanczyk","year":"2022","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2026.105659_bib77","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","article-title":"Functional precision oncology using patient-derived assays: bridging genotype and phenotype","volume":"20","author":"van Renterghem","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib78","article-title":"Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study","volume":"4","author":"Wang","year":"2023","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1193430","article-title":"A perfused multi-well bioreactor platform to assess tumor organoid response to a chemotherapeutic gradient","volume":"11","author":"Wasson","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13322","article-title":"Vasculogenic mimicry in small cell lung cancer","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2026.118565","article-title":"MASEA: A microfluidic system for in situ evaluation of tumor angiogenesis in PDO-endothelial co-culture","volume":"302","author":"Wu","year":"2026","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.critrevonc.2026.105659_bib82","first-page":"903","article-title":"Organoid models in oncology: Advancing precision cancer therapy and vaccine development","volume":"22","author":"Xiao","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.critrevonc.2026.105659_bib83","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105659_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1509195","article-title":"Angiogenesis and EMT regulators in the tumor microenvironment in lung cancer and immunotherapy","volume":"15","author":"Yan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib85","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of patient-derived tumor xenograft models and tumor organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105659_bib86","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10456-024-09905-z","article-title":"Vascularized organoid-on-a-chip: Design, imaging, and analysis","volume":"27","author":"Yu","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2026.105659_bib87","doi-asserted-by":"crossref","DOI":"10.1063\/5.0282002","article-title":"Microfluidic lung cancer models: Bridging clinical treatment strategies and tumor microenvironment recapitulation","volume":"9","author":"Yu","year":"2025","journal-title":"APL Bioeng."},{"key":"10.1016\/j.critrevonc.2026.105659_bib88","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1039\/D3LC00974B","article-title":"A dual-functional microfluidic chip for guiding personalized lung cancer medicine: Combining EGFR mutation detection and organoid-based drug response test","volume":"24","author":"Zhang","year":"2024","journal-title":"Lab. Chip"},{"key":"10.1016\/j.critrevonc.2026.105659_bib89","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1039\/D0LC01186J","article-title":"Vascularized organoids on a chip: Strategies for engineering organoids with functional vasculature","volume":"21","author":"Zhang","year":"2021","journal-title":"Lab. Chip"},{"key":"10.1016\/j.critrevonc.2026.105659_bib90","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1038\/s41467-024-47737-z","article-title":"A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105659_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22257","article-title":"A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies","volume":"85","author":"Zhao","year":"2024","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.critrevonc.2026.105659_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241270589","article-title":"Advances in predictive biomarkers for anti-angiogenic therapy in non-small cell lung cancer","volume":"31","author":"Zhao","year":"2024","journal-title":"Cancer Control."},{"key":"10.1016\/j.critrevonc.2026.105659_bib93","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.18632\/aging.204826","article-title":"PRMT5 facilitates angiogenesis and EMT via HIF-1\u03b1\/VEGFR\/Akt signaling axis in lung cancer","volume":"15","author":"Zheng","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.critrevonc.2026.105659_bib94","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105659_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70258","article-title":"Vascularised organoids: Recent advances and applications in cancer research","volume":"15","author":"Zhou","year":"2025","journal-title":"Clin. Transl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:41:34Z","timestamp":1793227294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":95,"alternative-id":["S1040842826005469"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105659","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung cancer organoid models for studying resistance to anti-angiogenic therapy: Mechanisms and applications","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105659"}}